AIM ImmunoTech Inc. (AIM)
NYSE
Closed
Aug 24, 2026
Day's Range
0.246752 wk Range
0.1900Overview - AIM - AIM ImmunoTech Inc.
Key Statistics
Valuation
Enterprise Value
1.82M
P/E (Trailing)
‪-0.03‬
P/E (Forward)
‪-0.69‬
PEG Ratio
‪0.00035‬
Price / Sales (TTM)
‪82.80‬
Price / Book
‪0.96‬
EV / EBITDA
‪-0.17‬
Profitability
Gross Margin
‪81.81%‬
Profit Margin
‪-45.45%‬
Operating Margin
‪-13,511.53%‬
Return on Assets
‪-82.57%‬
Return on Equity
‪-2,382.30%‬
Ownership
Shares Outstanding
8.22M
Float
27.68M
Short % of Shares Outstanding
‪3.30%‬
Held by Insiders
‪0.53%‬
Held by Institutions
‪3.87%‬
Price stats
Beta
‪1.19‬
50-Day Avg
‪0.2898‬
200-Day Avg
‪0.7724‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
2 analysts
Average price target
‪$ 5.25‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - AIM - AIM ImmunoTech Inc.
Peers - AIM - AIM ImmunoTech Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NYSE.
- AIMNYSEAIM ImmunoTech Inc.7.86MMarket Cap-873.66%52-week change-0.03P/E (Trailing)‪-45.45%‬Profit Margin
- BIONYSEBio-Rad Laboratories Inc.10.20BMarket Cap+22.11%52-week change46.29P/E (Trailing)‪8.58%‬Profit Margin
- BHVNNYSEBiohaven Ltd.2.09BMarket Cap-7.95%52-week change-2.01P/E (Trailing)‪0.00%‬Profit Margin
- BSTNYSEBlackRock Science and Technology Trust1.70BMarket Cap+19.91%52-week change6.87P/E (Trailing)‪0.00%‬Profit Margin
- ANRONYSEAlto Neuroscience Inc.1.34BMarket Cap+88.51%52-week change-15.62P/E (Trailing)‪0.00%‬Profit Margin
- BCXNYSEBlackRock Resources & Commodities Strategy Trust1.00BMarket Cap+25.40%52-week change4.72P/E (Trailing)‪0.00%‬Profit Margin
- ATTONYSEAttovia Therapeutics Inc.887.25MMarket Cap-6.21%52-week change-8.75P/E (Trailing)‪0.00%‬Profit Margin
Profile Summary - AIM - AIM ImmunoTech Inc.
About
AIM ImmunoTech Inc. is a biopharmaceutical company specializing in immunology-focused drug development. The company concentrates on researching and developing therapeutics for multiple types of cancers, viral diseases, immune disorders, and immune-deficiency conditions, addressing areas where existing treatment…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
